The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity

被引:53
作者
Doyle, ME
Theodorakis, MJ
Holloway, HW
Bernier, M
Greig, NH
Egan, JM
机构
[1] NIA, Diabet Sect 23, NIH, Baltimore, MD 21224 USA
[2] NIA, Drug Design & Dev Sect, NIH, Baltimore, MD 21224 USA
关键词
insulinotropic compounds; peptide structure/function;
D O I
10.1016/S0167-0115(03)00120-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Exendin-4. a 39-amino acid (AA) peptide, is a long-acting agonist at the glucagon-like peptide-1 (GLP-1) receptor. Consequently, it may be preferable to GLP-1 as a long-term treatment for type 2 diabetes mellitus. Exendin-4 (Ex-4), unlike GLP-1, is not degraded by dipeptidyl peptidase IV (DPP IV), is less susceptible to degradation by neutral endopeptidase, and possesses a nine-AA C-terminal sequence absent from GLP-1. Here we examine the importance of these nine AAs for biological activity of Ex-4, a sequence of truncated Ex-4 analogs, and native GLP-1 and GLP-1 analogs to which all or parts of the C-terminal sequence have been added. We found that removing these AAs from Ex-4 to produce Ex (1-30) reduced the affinity for the GLP-1 receptor (GLP-1R) relative to Ex-4 (IC50: Ex-4, 3.22 +/- 0.9 nM; Ex (1-30), 32 5.8 nM) but made it comparable to that of GLP-1 (IC50: 44.9 +/- 3.2 nM). The addition of this nine-AA sequence to GLP-1 improved the affinity of both GLP-1 and the DPP IV resistant analog GLP-1 8-glycine for the GLP-1 receptor (IC50: GLP-1 Gly(8) [GG], 220 +/- 23 nM; GLP-1 Gly(8) Ex (31-39) 74 +/- 11 nM). Observations of the cAMP response in an insulinoma cell line show a similar trend for biological activity. Published by Elsevier Science B.V.
引用
收藏
页码:153 / 158
页数:6
相关论文
共 20 条
[1]   Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1 [J].
Burcelin, R ;
Dolci, W ;
Thorens, B .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1999, 48 (02) :252-258
[2]   Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity [J].
Deacon, CF ;
Knudsen, LB ;
Madsen, K ;
Wiberg, FC ;
Jacobsen, O ;
Holst, JJ .
DIABETOLOGIA, 1998, 41 (03) :271-278
[3]  
DELEAN A, 1988, USERS GUIDE ALLFIT
[4]   Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent [J].
Doyle, ME ;
Greig, NH ;
Holloway, HW ;
Betkey, JA ;
Bernier, M ;
Egan, JM .
ENDOCRINOLOGY, 2001, 142 (10) :4462-4468
[5]   Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers [J].
Edwards, CMB ;
Stanley, SA ;
Davis, R ;
Brynes, AE ;
Frost, GS ;
Seal, LJ ;
Ghatei, MA ;
Bloom, SR .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2001, 281 (01) :E155-E161
[6]   The insulinotropic effect of acute exendin-4 administered to humans: Comparison of nondiabetic state to type 2 diabetes [J].
Egan, JM ;
Clocquet, AR ;
Elahi, D .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (03) :1282-1290
[7]  
ENG J, 1992, J BIOL CHEM, V267, P7402
[8]   Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations [J].
Greig, NH ;
Holloway, HW ;
De Ore, KA ;
Jani, D ;
Wang, Y ;
Zhou, J ;
Garant, MJ ;
Egan, JM .
DIABETOLOGIA, 1999, 42 (01) :45-50
[9]   Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine [J].
Hansen, L ;
Deacon, CF ;
Orskov, C ;
Holst, JJ .
ENDOCRINOLOGY, 1999, 140 (11) :5356-5363
[10]   CHARACTERIZATION OF THE PROCESSING BY HUMAN NEUTRAL ENDOPEPTIDASE-24.11 OF GLP-1(7-36) AMIDE AND COMPARISON OF THE SUBSTRATE-SPECIFICITY OF THE ENZYME FOR OTHER GLUCAGON-LIKE PEPTIDES [J].
HUPESODMANN, K ;
MCGREGOR, GP ;
BRIDENBAUGH, R ;
RUDIGER, G ;
BURKHARD, G ;
THOLE, H ;
ZIMMERMANN, B ;
VOIGT, K .
REGULATORY PEPTIDES, 1995, 58 (03) :149-156